• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Cureus . Autoimmune Rhombencephalitis as a Presentation of Post-COVID-19 Syndrome: A Case Report

tetano

Editor, Senior Moderator
Cureus


. 2025 Feb 23;17(2):e79517.
doi: 10.7759/cureus.79517. eCollection 2025 Feb. Autoimmune Rhombencephalitis as a Presentation of Post-COVID-19 Syndrome: A Case Report

Alaa S Mohamed[SUP] 1 [/SUP], Neesha Jahani[SUP] 2 [/SUP], Mingyu Li[SUP] 2 [/SUP], Manan Shah[SUP] 2 [/SUP], Askiel Bruno[SUP] 2 [/SUP], Dilip Singh[SUP] 2 [/SUP]



Affiliations
Abstract

There has been a multitude of neurological sequelae associated with the 2019 SARS-CoV-2 outbreak. We describe a unique case of a 31-year-old individual who developed post-infectious autoimmune rhombencephalitis approximately two weeks after testing positive for coronavirus disease 2019 (COVID-19). Treatment with high-dose corticosteroids with four weeks of taper resulted in excellent clinical recovery without any relapse. Thus, our findings support the use of immunotherapy as a potential treatment in cases of post-COVID-19 autoimmune rhombencephalitis. Furthermore, this case highlights the importance of considering post-infectious COVID-19 sequelae as a differential diagnosis in patients presenting with rhombencephalitis in the appropriate clinical setting.

Keywords: autoimmune; brain stem; cerebellum; covid 19; post-covid-19; rhombencephalitis; sars-cov.

 
Back
Top Bottom